{"id":40705,"date":"2025-09-04T15:36:47","date_gmt":"2025-09-04T07:36:47","guid":{"rendered":"https:\/\/flcube.com\/?p=40705"},"modified":"2025-09-04T15:36:48","modified_gmt":"2025-09-04T07:36:48","slug":"hengruis-hrs9531-injection-clears-nmpa-approval-hits-19-2-weight-loss-in-phase-3","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=40705","title":{"rendered":"Hengrui\u2019s HRS9531 Injection Clears NMPA Approval, Hits 19.2% Weight Loss in Phase\u202f3"},"content":{"rendered":"\n<p>China\u2011based\u00a0<strong>Jiangsu Hengrui Pharmaceuticals Co., Ltd.<\/strong> (<a href=\"https:\/\/www.google.com\/finance\/quote\/1276:HKG\">HKG: 1276<\/a>, <a href=\"https:\/\/www.google.com\/finance\/quote\/600276:SHA\">SHA: 600276<\/a>) confirmed that China\u2019s National Medical Products Administration (NMPA) has accepted the marketing filing for its <strong>HRS9531 Injection<\/strong>, a novel dual agonist targeting the <strong>GLP\u20111<\/strong> and <strong>GIP<\/strong> receptors for long\u2011term weight management.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-product-profile\">Product Profile<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Indication<\/strong> \u2013 Adults with <strong>BMI\u202f\u2265\u202f28\u202fkg\/m\u00b2<\/strong> (obesity) or <strong>BMI\u202f\u2265\u202f24\u202fkg\/m\u00b2<\/strong> (overweight) plus at least one weight\u2011related comorbidity (hyperglycemia, hypertension, dyslipidemia, OSA, fatty liver, etc.).<\/li>\n\n\n\n<li><strong>Mechanism<\/strong> \u2013 Dual GLP\u20111\/GIP receptor agonist, developed in\u2011house, designed to enhance satiety and improve insulin sensitivity.<\/li>\n\n\n\n<li><strong>Safety<\/strong> \u2013 Phase\u202f3 data demonstrate a favorable safety and tolerability profile.<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-phase-3-success\">Phase\u202f3 Success<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Metric<\/th><th>Result<\/th><\/tr><\/thead><tbody><tr><td><strong>Primary Endpoint<\/strong><\/td><td>Met (significant weight reduction vs. placebo)<\/td><\/tr><tr><td><strong>Key Secondary Endpoints<\/strong><\/td><td>Met (including waist circumference, HbA1c, BP)<\/td><\/tr><tr><td><strong>High\u2011Dose Mean Weight Loss<\/strong><\/td><td><strong>19.2\u202f%<\/strong><\/td><\/tr><tr><td><strong>\u226520\u202f% Weight Loss<\/strong><\/td><td><strong>44.4\u202f%<\/strong> of subjects<\/td><\/tr><tr><td><strong>Trial Size<\/strong><\/td><td>567 adults with obesity\/overweight + comorbidity<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<p>The clinical trial (HRS9531\u2011301) enrolled 567 participants, achieving all primary and key secondary endpoints, positioning HRS9531 as a strong contender in the obesity\u2011drug market.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-global-licensing-amp-commercial-strategy\">Global Licensing &amp; Commercial Strategy<\/h2>\n\n\n\n<p>In May\u202f2024, Hengrui licensed the <strong>global rights (excluding Greater China)<\/strong> to <strong>Kailera Therapeutics<\/strong> for the development, production, and commercialization of HRS9531. Key terms:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Upfront Payment + Milestones<\/strong> \u2013 Totaling <strong>>\u202f$6\u202fB<\/strong>.<\/li>\n\n\n\n<li><strong>Equity<\/strong> \u2013 Hengrui acquired a <strong>19.9\u202f%<\/strong> stake in Kailera.<\/li>\n\n\n\n<li><strong>Exclusivity<\/strong> \u2013 Kailera holds exclusive rights outside China, ensuring a focused global rollout.<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-implications-for-the-market\">Implications for the Market<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Competitive Edge<\/strong> \u2013 The dual\u2011agonist mechanism offers a differentiated profile versus existing GLP\u20111 monotherapies.<\/li>\n\n\n\n<li><strong>Growth Potential<\/strong> \u2013 With 44.4\u202f% of high\u2011dose patients losing \u226520\u202f% of body weight, HRS9531 could capture a sizable share of the obesity\u2011treatment segment.<\/li>\n\n\n\n<li><strong>Strategic Partnership<\/strong> \u2013 The $6\u202fB milestone package underscores investor confidence and provides a robust pipeline for Kailera.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/li>\n<\/ul>\n\n\n\n<div data-wp-interactive=\"core\/file\" class=\"wp-block-file\"><object data-wp-bind--hidden=\"!state.hasPdfPreview\" hidden class=\"wp-block-file__embed\" data=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/09\/600276_20250902_866R.pdf\" type=\"application\/pdf\" style=\"width:100%;height:600px\" aria-label=\"Embed of 600276_20250902_866R.\"><\/object><a id=\"wp-block-file--media-e795bf27-6b55-4a3c-b001-b15f88e98389\" href=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/09\/600276_20250902_866R.pdf\">600276_20250902_866R<\/a><a href=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/09\/600276_20250902_866R.pdf\" class=\"wp-block-file__button wp-element-button\" download aria-describedby=\"wp-block-file--media-e795bf27-6b55-4a3c-b001-b15f88e98389\">Download<\/a><\/div>\n","protected":false},"excerpt":{"rendered":"<p>China\u2011based\u00a0Jiangsu Hengrui Pharmaceuticals Co., Ltd. (HKG: 1276, SHA: 600276) confirmed that China\u2019s National Medical Products&#8230;<\/p>\n","protected":false},"author":1,"featured_media":40707,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,11],"tags":[4228,38,86,852],"class_list":["post-40705","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-drug","tag-hkg-1276","tag-market-approval-filings","tag-obesity","tag-sha-600276"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.5) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Hengrui\u2019s HRS9531 Injection Clears NMPA Approval, Hits 19.2% Weight Loss in Phase\u202f3 - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"China\u2019s Jiangsu\u202fHengrui Pharmaceuticals (SHA: 600276, HKG: 1276) announced that the NMPA accepted its filing for HRS9531 Injection, a dual GLP\u20111\/GIP agonist. The drug achieved the primary endpoint and 19.2% mean weight loss in a 567\u2011patient Phase\u202f3 trial and is now licensed to Kailera Therapeutics outside Greater China for a $6\u202fB+ milestone package.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=40705\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Hengrui\u2019s HRS9531 Injection Clears NMPA Approval, Hits 19.2% Weight Loss in Phase\u202f3\" \/>\n<meta property=\"og:description\" content=\"China\u2019s Jiangsu\u202fHengrui Pharmaceuticals (SHA: 600276, HKG: 1276) announced that the NMPA accepted its filing for HRS9531 Injection, a dual GLP\u20111\/GIP agonist. The drug achieved the primary endpoint and 19.2% mean weight loss in a 567\u2011patient Phase\u202f3 trial and is now licensed to Kailera Therapeutics outside Greater China for a $6\u202fB+ milestone package.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=40705\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2025-09-04T07:36:47+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-09-04T07:36:48+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/09\/0412.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=40705#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=40705\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Hengrui\u2019s HRS9531 Injection Clears NMPA Approval, Hits 19.2% Weight Loss in Phase\u202f3\",\"datePublished\":\"2025-09-04T07:36:47+00:00\",\"dateModified\":\"2025-09-04T07:36:48+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=40705\"},\"wordCount\":285,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=40705#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/09\\\/0412.webp\",\"keywords\":[\"HKG: 1276\",\"Market approval filings\",\"Obesity\",\"SHA: 600276\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=40705#respond\"]}],\"copyrightYear\":\"2025\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=40705\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=40705\",\"name\":\"Hengrui\u2019s HRS9531 Injection Clears NMPA Approval, Hits 19.2% Weight Loss in Phase\u202f3 - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=40705#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=40705#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/09\\\/0412.webp\",\"datePublished\":\"2025-09-04T07:36:47+00:00\",\"dateModified\":\"2025-09-04T07:36:48+00:00\",\"description\":\"China\u2019s Jiangsu\u202fHengrui Pharmaceuticals (SHA: 600276, HKG: 1276) announced that the NMPA accepted its filing for HRS9531 Injection, a dual GLP\u20111\\\/GIP agonist. The drug achieved the primary endpoint and 19.2% mean weight loss in a 567\u2011patient Phase\u202f3 trial and is now licensed to Kailera Therapeutics outside Greater China for a $6\u202fB+ milestone package.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=40705#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=40705\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=40705#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/09\\\/0412.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/09\\\/0412.webp\",\"width\":1080,\"height\":608,\"caption\":\"Hengrui\u2019s HRS9531 Injection Clears NMPA Approval, Hits 19.2% Weight Loss in Phase\u202f3\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=40705#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Hengrui\u2019s HRS9531 Injection Clears NMPA Approval, Hits 19.2% Weight Loss in Phase\u202f3\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Hengrui\u2019s HRS9531 Injection Clears NMPA Approval, Hits 19.2% Weight Loss in Phase\u202f3 - Insight, China&#039;s Pharmaceutical Industry","description":"China\u2019s Jiangsu\u202fHengrui Pharmaceuticals (SHA: 600276, HKG: 1276) announced that the NMPA accepted its filing for HRS9531 Injection, a dual GLP\u20111\/GIP agonist. The drug achieved the primary endpoint and 19.2% mean weight loss in a 567\u2011patient Phase\u202f3 trial and is now licensed to Kailera Therapeutics outside Greater China for a $6\u202fB+ milestone package.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=40705","og_locale":"en_US","og_type":"article","og_title":"Hengrui\u2019s HRS9531 Injection Clears NMPA Approval, Hits 19.2% Weight Loss in Phase\u202f3","og_description":"China\u2019s Jiangsu\u202fHengrui Pharmaceuticals (SHA: 600276, HKG: 1276) announced that the NMPA accepted its filing for HRS9531 Injection, a dual GLP\u20111\/GIP agonist. The drug achieved the primary endpoint and 19.2% mean weight loss in a 567\u2011patient Phase\u202f3 trial and is now licensed to Kailera Therapeutics outside Greater China for a $6\u202fB+ milestone package.","og_url":"https:\/\/flcube.com\/?p=40705","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2025-09-04T07:36:47+00:00","article_modified_time":"2025-09-04T07:36:48+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/09\/0412.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=40705#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=40705"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Hengrui\u2019s HRS9531 Injection Clears NMPA Approval, Hits 19.2% Weight Loss in Phase\u202f3","datePublished":"2025-09-04T07:36:47+00:00","dateModified":"2025-09-04T07:36:48+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=40705"},"wordCount":285,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=40705#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/09\/0412.webp","keywords":["HKG: 1276","Market approval filings","Obesity","SHA: 600276"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=40705#respond"]}],"copyrightYear":"2025","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=40705","url":"https:\/\/flcube.com\/?p=40705","name":"Hengrui\u2019s HRS9531 Injection Clears NMPA Approval, Hits 19.2% Weight Loss in Phase\u202f3 - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=40705#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=40705#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/09\/0412.webp","datePublished":"2025-09-04T07:36:47+00:00","dateModified":"2025-09-04T07:36:48+00:00","description":"China\u2019s Jiangsu\u202fHengrui Pharmaceuticals (SHA: 600276, HKG: 1276) announced that the NMPA accepted its filing for HRS9531 Injection, a dual GLP\u20111\/GIP agonist. The drug achieved the primary endpoint and 19.2% mean weight loss in a 567\u2011patient Phase\u202f3 trial and is now licensed to Kailera Therapeutics outside Greater China for a $6\u202fB+ milestone package.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=40705#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=40705"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=40705#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/09\/0412.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/09\/0412.webp","width":1080,"height":608,"caption":"Hengrui\u2019s HRS9531 Injection Clears NMPA Approval, Hits 19.2% Weight Loss in Phase\u202f3"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=40705#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Hengrui\u2019s HRS9531 Injection Clears NMPA Approval, Hits 19.2% Weight Loss in Phase\u202f3"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/09\/0412.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/40705","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=40705"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/40705\/revisions"}],"predecessor-version":[{"id":40708,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/40705\/revisions\/40708"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/40707"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=40705"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=40705"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=40705"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}